融合素的候选先导药物是西夫韦肽，一种HIV融合抑制剂。
The lead drug candidate in FusoGen's pipeline is Sifuvirtide, an HIV fusion inhibitor.
人们怀着谨慎乐观的态度发行了第一个融合抑制剂——福泽昂。
Cautious optimism emerges with the release of the first entry inhibitor, Fuzeon.
扶素生物自主开发的第一个产品：艾滋病病毒膜融合抑制剂——西夫韦肽。
The lead drug candidate in FusoGen's pipeline is Sifuvirtide, an HIV fusion inhibitor. One of the first fusion inhibitor drug against HIV.
包括单克隆抗体、酪氨酸激酶抑制剂、融合蛋白、瘤苗在内，以her2为靶点的抗肿瘤治疗研究成为热点，并显示出广阔的应用前景。
Anticancer therapies targeting HER2 have shown promise and become a focus, including monoclonal antibody, tyrosine kinases inhibitor, tumor vaccine, fusion protein.
包括单克隆抗体、酪氨酸激酶抑制剂、融合蛋白、瘤苗在内，以her2为靶点的抗肿瘤治疗研究成为热点，并显示出广阔的应用前景。
Anticancer therapies targeting HER2 have shown promise and become a focus, including monoclonal antibody, tyrosine kinases inhibitor, tumor vaccine, fusion protein.
应用推荐